Accurate understanding of tumor characteristics
Information at the molecular level helps medical teams gain a deeper understanding of tumor characteristics.
Each patient’s tumor biology and physical condition may be different.
Personalized analysis, through advanced testing technology, provides medical teams with more information,
helping to explore more suitable health management directions and follow-up plans.
- Treatment response rates show an improving trend
- Progression-free survival has been extended in some individuals
- Overall survival observations indicate potential for improvement
Contact our professional team to learn more about our liquid biopsy services.
What are the potential benefits for you?
It helps identify care options that may be more suitable for your specific cancer characteristics, thus supporting better treatment outcomes; it also helps reduce unnecessary physical burden and side effects caused by unsuitable care plans.
Clinical Observational Comparison: Matched vs Non-Matched Therapy
- ✓ Detects gene mutation information
- ✓ Helps track tumor genetic changes
- ✓ Suitable for long-term molecular monitoring
- ✕ Does not provide intact viable tumor cells
- ✓ Provides intact tumor cells for analysis
- ✓ Enables drug sensitivity testing
- ✓ Has prognostic reference value in multiple solid tumors
- ✕ Not primarily used for detailed mutation tracking
References
| # | Study | Year | Key Findings |
|---|---|---|---|
| 6 | Tsimberidou AM et al. MD Anderson personalized medicine study in advanced cancer. | 2014 | Response rate 12% vs 5%; progression-free survival 4 vs 2 months; overall survival 11 vs 9 months. |
| 7 | IMPACT study – MD Anderson precision medicine program. | 2017 | Matched therapy associated with improved response rates and survival observations. |
| 8 | UCSD Moores Cancer Center PREDICT study. | 2016 | Disease stabilization/improvement 35% vs 16%; extended progression-free duration. |
| 9 | Real-world molecular tumor board data in breast and gynecologic cancers. | 2022 | Response rate 31% vs 7%; reduced risk of disease progression. |
| 10 | Herzog TJ et al. ChemoID-guided ovarian cancer study. | 2025 | Response rate 55% vs 5%; progression-free survival 11 vs 3 months. |
| 11 | Tsimberidou AM et al. IMPACT program (JCO). | 2012 | Matched therapy showed improved response and survival observations compared to non-matched therapy. |
| 12 | Von Hoff DD et al. Molecular profiling–guided therapy study (JCO). | 2010 | Targeted strategies demonstrated longer progression-free duration compared to prior treatments. |
| 13 | Alix-Panabières C, Pantel K. Clinical applications of CTC and ctDNA. | 2016 | CTCs provide prognostic insight across multiple solid tumors; ctDNA suitable for mutation tracking. |
| 14 | Pediatric MATCH trial (National Cancer Institute). | 2020 | 2-year progression-free rate 26% vs 12% in molecularly matched pediatric cases. |
| 15 | MD Anderson IMPACT long-term follow-up analysis. | 2019 | Matched targeted strategies associated with improved overall survival observations. |
Contact our professional team to learn more about our liquid biopsy services.
What are the potential benefits for you?
It helps identify care options that may be more suitable for your specific cancer characteristics, thus supporting better treatment outcomes; it also helps reduce unnecessary physical burden and side effects caused by unsuitable care plans.
Medical Disclaimer:
The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.